Insider plans Rule 144 sale of 17,000 shares

David S. Bredt filed a notice of proposed sale under Rule 144 to sell 17,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.

Rhea-AI Filing Summary

David S. Bredt filed a notice of proposed sale under Rule 144 to sell 17,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. The filing lists an aggregate market value of $466,140.00 for these shares and notes that 47,661,138 shares of the issuer’s common stock are outstanding.

The shares to be sold were acquired as founder shares on 03/09/2023, with 17,000 securities acquired and paid for on the same date. Over the past three months, related sales of common stock by David S. Bredt include 6,567 shares sold on 12/31/2025 for $197,337.69, 8,500 shares sold on 12/15/2025 for $255,130.05, and 8,500 shares sold on 11/17/2025 for $214,090.35, with two of these transactions identified as Rule 10b5-1 sales.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RAPP shares are planned to be sold under this Rule 144 filing?

The notice states that 17,000 shares of common stock are planned to be sold under Rule 144.

What is the aggregate market value of the RAPP shares to be sold?

The filing lists an aggregate market value of $466,140.00 for the 17,000 shares of common stock to be sold.

Which broker and exchange are involved in this RAPP Rule 144 sale?

The planned sale is through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.

When were the RAPP shares to be sold under Rule 144 originally acquired?

The 17,000 common shares to be sold were acquired as founder shares on 03/09/2023, with payment made on the same date.

How many RAPP shares has David S. Bredt sold in the past three months?

The filing lists sales of 6,567 shares on 12/31/2025, 8,500 shares on 12/15/2025, and 8,500 shares on 11/17/2025, all in common stock.

Are any of the recent RAPP share sales under a Rule 10b5-1 trading plan?

Yes. The sales of 8,500 shares on 12/15/2025 and 8,500 shares on 11/17/2025 are identified as 10b5-1 sales for David S. Bredt.

How many RAPP common shares are outstanding according to this filing?

The filing states that 47,661,138 shares of the issuer’s common stock are outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002022087
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	RAPPORT THERAPEUTICS INC
SEC File Number	001-42121
Address of Issuer	99 High Street, Suite 2100 Boston MASSACHUSETTS 02110
Phone	8573218020
Name of Person for Whose Account the Securities are To Be Sold	DAVID BREDT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	17000	466140.00	47661138	01/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/09/2023	Founders Shares	17000			17000	03/09/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DAVID S BREDT 99 High Street, Suite 2100 Boston MA 02110	Common	12/31/2025	6567	197337.69
10b5-1 Sales for DAVID S BREDT 99 High Street, Suite 2100 Boston MA 02110	Common	12/15/2025	8500	255130.05
10b5-1 Sales for DAVID S BREDT 99 High Street, Suite 2100 Boston MA 02110	Common	11/17/2025	8500	214090.35

144: Remarks and Signature

Remarks	The securities to be sold were acquired as Founder Shares during the period of 3/9/2023 through 6/9/2023.
Date of Notice	01/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/12/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ David Scott Bredt
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)